Praxis Precision Medicines (PRAX) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Praxis Precision Medicines (NASDAQ: PRAX):

• 12/1/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $250.00 price target on the stock.
• 11/25/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $258.00 price target on the stock.
• 11/19/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Praxis Precision Medicines was upgraded by analysts at Chardan Capital to a “strong-buy” rating.
• 11/18/2025 – Praxis Precision Medicines was given a new $424.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
• 11/18/2025 – Praxis Precision Medicines was upgraded by analysts at BTIG Research to a “strong-buy” rating.
• 11/13/2025 – Praxis Precision Medicines had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Praxis Precision Medicines had its price target raised by analysts at HC Wainwright from $232.00 to $258.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $540.00 price target on the stock.
• 11/6/2025 – Praxis Precision Medicines had its price target raised by analysts at Wedbush from $73.00 to $77.00. They now have an “underperform” rating on the stock.
• 10/20/2025 – Praxis Precision Medicines had its price target raised by analysts at Wedbush from $33.00 to $73.00. They now have an “underperform” rating on the stock.
• 10/17/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a $280.00 price target on the stock, up previously from $65.00.
• 10/17/2025 – Praxis Precision Medicines was given a new $330.00 price target on by analysts at Chardan Capital. They now have a “buy” rating on the stock.
• 10/17/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $360.00 price target on the stock, up previously from $85.00.
• 10/16/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $300.00 price target on the stock, up previously from $65.00.
• 10/16/2025 – Praxis Precision Medicines was given a new $350.00 price target on by analysts at Guggenheim. They now have a “buy” rating on the stock.
• 10/16/2025 – Praxis Precision Medicines had its price target raised by analysts at HC Wainwright from $115.00 to $232.00. They now have a “buy” rating on the stock.
• 10/16/2025 – Praxis Precision Medicines had its price target raised by analysts at Needham & Company LLC from $80.00 to $250.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Praxis Precision Medicines had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at Praxis Precision Medicines

In other news, insider Lauren Mastrocola sold 13,600 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the completion of the sale, the insider directly owned 10,442 shares of the company’s stock, valued at approximately $2,005,699.36. The trade was a 56.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Alex Nemiroff sold 25,130 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the transaction, the general counsel owned 20,832 shares of the company’s stock, valued at approximately $4,022,450.88. The trade was a 54.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 2.70% of the company’s stock.

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.